Pulmonary hypertension epidemiology and demographics: Difference between revisions
Ralph Matar (talk | contribs) No edit summary |
Ralph Matar (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Epidemiology== | ==Epidemiology== | ||
While previously considered a rare disease, the most recent evidence from a French registry suggests that the prevalence of Pulmonary arterial hypertension is about 15 per million. | While previously considered a rare disease, the most recent evidence from a French registry suggests that the prevalence of Pulmonary arterial hypertension is about 15 per million. Pulmonary Hypertension usually develops between the ages of 20 and 60, but it can occur at any age. | ||
'''Idiopathic pulmonary hypertension'''which is more prevalent in women, was considered the most common type of | '''Idiopathic pulmonary hypertension''' which is more prevalent in women, was considered the most common type of Pulmonary arterial hypertension in a French registry. | ||
'''Familial PAH''' often results from a mutation in the bone morphogenic protein receptor-2 (BMPR2) and is inherited as an autosomal dominant disease with incomplete penetrance and anticipation. | '''Familial PAH''' often results from a mutation in the bone morphogenic protein receptor-2 (BMPR2) and is inherited as an autosomal dominant disease with incomplete penetrance and anticipation. | ||
Revision as of 18:30, 7 September 2011
Epidemiology
While previously considered a rare disease, the most recent evidence from a French registry suggests that the prevalence of Pulmonary arterial hypertension is about 15 per million. Pulmonary Hypertension usually develops between the ages of 20 and 60, but it can occur at any age.
Idiopathic pulmonary hypertension which is more prevalent in women, was considered the most common type of Pulmonary arterial hypertension in a French registry.
Familial PAH often results from a mutation in the bone morphogenic protein receptor-2 (BMPR2) and is inherited as an autosomal dominant disease with incomplete penetrance and anticipation.
PAH is also associated with congenital heart disease(30% of untreated), connective tissue diseases like systemic sclerosis(12% of patients), drugs and toxins, HIV, portal hypertension(2-6%), hemoglobinopathies, and myeloproliferative disorders.[1]
Mortality rate is 5.2-5.4 per 100000 and was more common in African-Americans and women.
The most common cause of hospitilization is heart failure whereas, the most common cause of death is pulmonary hypertension itself and not chronic lower respiratory disease as was once thought.
- ↑ ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension